CHROMOSOME ABERRATIONS OUTCOME IN CANCER PATIENTS AT THE BEGINNING OF RADIOTHERAPY COURSE ON ROCUS-AM AND LINEAR ACCELERATOR CLINAC 600C
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-21-2-2019-g.7165Keywords:
chromosome aberrations, gamma-therapy, head and neck cancer, lung cancer, megavolt therapy on the linear accelerator, uterine body cancerAbstract
Aim: the detection of chromosome aberrations level at the beginning of radiation therapy in cancer patients with different tumor localizations (uterine body cancer (UBC), lung cancer (LC) and head and neck cancer (HNC)) depending on the source of irradiation. Object and methods: 45 patients with UBC (21), LC (16) and HNC (8) were examined. Cytogenetic analysis was carried out before the start of treatment and 24 hours after receiving the first fraction of gamma-therapy 60Co on ROKUS-AM or megavolt therapy on the linear accelerator Clinac 600C. Results: an increase of chromosomal aberrations frequency in oncogynecological patients and LC patients already after the first fraction of external gamma- and megavolt radiation therapy was shown. There was no significant difference in cytogenetic damages outcome between the radiation sources used in radiation treatment. However the increase of dicentrics level in oncogynecological patients was two times higher in comparison with that of in LC patients and was equal to 9-fold and 4.5-fold, respectively, in relation to before treatment values. Regardless to the radiation source, the excess acentric fragments level with the radiotherapy start increased 1.8-fold in both patient groups. The intensity of the radiation-induced lesions formation depended on the tumor localization. The statistically significant enhance was found for total frequency and particular kinds of chromosome aberration in oncogynecological patients comparing with LC patients and HNC patients. The ratio of unstable chromosome type aberrations in oncogynecological, LC and HNC patients was 1 : 0.67 : 0.57. The distribution of the chromosome type aberrations among cells after first fraction of radiation treatment was found to be over-dispersed according to Poisson statistic in all studied groups. Conclusion: analysis of cytogenetic damages revealed the increase of chromosome aberrations yield already after first radiotherapy fraction both on ROCUS-AM and Clinac 600C, and the difference in lesions accumulation in patients depending on tumor localization. In patients with the largest volume of irradiated body fraction, namely oncogynecological patients, the highest level of chromosome type aberrations was observed in comparison with LC and HNC patients. The data obtained are of importance for correct estimation of radiation treatment effects in non-tumor cells.
References
Thariat J, Hannoun-Levi JM, Sun Myint A, Vuong T, et al. Past, present, and future of radiotherapy for the benefit of patients. Nat Rev Clin Oncol 2013; 10 (1): 52–60.
Vinogradov VM. Perspective methods of radiation therapy. Practical Oncol 2007; 8 (1): 194–204 (in Russian).
Muller I, Geinitz H, Braselmann H, et al. Time-course of radiation-induced chromosomal aberrations in tumor patients after radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63 (4): 1214–20.
Tawn EJ, Whitehouse CA. Persistence of translocation frequencies in blood lymphocytes following radiotherapy: implications for retrospective radiation biodosimetry. J Radiol Prot 2003; 23 (4): 423–30.
Khvostunov IK, Kursova LV, Shepel NN, et al. The estimation of appropriateness of chromosomal aberration assay as a biological dosimetry based on cytogenetic investigation of lung cancer patients given non-uniform fractional exposures to high doses of therapeutic 60Co γ-rays. Radiat Biol Radioecol 2012; 52 (5): 467–80 (in Russian).
Roch-Lefevre S, Pouzoulet F, Giraudet AL, et al. Cytogenetic assessment of heterogeneous radiation doses in cancer patients treated with fractionated radiotherapy. Br J Radiol 2010; 83 (993): 759–66.
Fong L, Chen JY, Ting LL, et al. Chromosome aberrations induced in human lymphocytes after partial-body irradiation. Radiat Res 1995; 144 (1): 97–101.
Sreedevi B, Rao BS, Nagaraj H, Pal NK. Chromosome aberration analysis in radiotherapy patients and simulated partial body exposures: biological dosimetry for non-uniform exposures. Radiat Prot Dosim 2001; 94 (4): 317–22.
Cytogenetic dosimetry: applications in preparedness for and response to radiation emergencies 2011; Vienna: International Atomic Energy Agency. 229 p.
Higueras M, Gonzalez JE, Di Giorgio M, Barquinero JF. A note on Poisson goodness-of-fit tests for ionizing radiation induced chromosomal aberration samples. Int J Radiat Biol 2018; 94 (7): 656–63.
Atramentova LA, Utevskaya OM. Statistical methods in biology. Gorlovka: Vydavnytstvo Likhtar, 2008. 248 p. (in Russian).
Maznyk NO, Vinnikov VA, Mikhanovskyi OA, et al. Cytogenetic effects in patients with cervical and ovarian cancers undergoing radiation therapy. Ukr Radiol Zhurnal 2002; 10 (1): 32–6 (in Ukrainian).
Senthamizhchelvan S, Pant GS, Rath GK, et al. Biodosimetry using micronucleus assay in acute partial body therapeutic irradiation. Phys Med 2009; 25 (2): 82–7.
Dіomina EA, Ivankova VS. The individual radiation sensitivity of cancer patients: radiobiological and clinical aspects. Neoplasm 2012; 1–2 (9–10): 201–5 (in Ukrainian).
